Ifosfamide in the treatment of non-small cell lung cancer

Research output: Contribution to journalReview articlepeer-review


Thirteen single-agent and 23 combination chemotherapeutic regimen trials using ifosfamide involving 1,326 evaluable patients with non-small cell lung cancer were reviewed. From these studies, several conclusions can be drawn: (1) Ifosfamide as a single agent shows response rates greater than 20%; (2) in combination with cisplatin, with or without a third drug, ifosfamide induces response rates of 38%; however, survival is not increased significantly; (3) other combinations with ifosfamide have a response rate greater than 35%; and (4) ifosfamide warrants continued evaluation and testing in combination with other effective agents.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalSeminars in oncology
Issue number1 SUPPL. 3
StatePublished - Jan 1 1989

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Ifosfamide in the treatment of non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this